EGFR and non-small cell lung carcinoma: Targeted therapies are emerging for the treatment of NSCLC, including epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor receptor (VEGF) inhibitors, and checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) pathway [2, 5].